Wall Street brokerages expect Teleflex Incorporated (NYSE:TFX) to post $601.67 million in sales for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Teleflex’s earnings, with the highest sales estimate coming in at $605.30 million and the lowest estimate coming in at $598.50 million. Teleflex reported sales of $513.93 million in the same quarter last year, which indicates a positive year-over-year growth rate of 17.1%. The business is expected to report its next quarterly earnings report on Thursday, February 22nd.

According to Zacks, analysts expect that Teleflex will report full-year sales of $601.67 million for the current year, with estimates ranging from $2.15 billion to $2.16 billion. For the next fiscal year, analysts anticipate that the business will report sales of $2.43 billion per share, with estimates ranging from $2.41 billion to $2.47 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Teleflex.

Teleflex (NYSE:TFX) last posted its quarterly earnings data on Thursday, November 2nd. The medical technology company reported $2.12 earnings per share for the quarter, topping the consensus estimate of $2.01 by $0.11. The firm had revenue of $534.70 million for the quarter, compared to analysts’ expectations of $522.94 million. Teleflex had a return on equity of 16.27% and a net margin of 12.41%. The company’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.80 EPS.

Several research analysts have weighed in on the company. Stephens reiterated a “buy” rating and set a $300.00 price objective on shares of Teleflex in a research report on Thursday. ValuEngine cut Teleflex from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Deutsche Bank cut Teleflex from a “buy” rating to a “hold” rating and set a $251.00 price objective on the stock. in a research report on Tuesday, November 14th. Piper Jaffray Companies assumed coverage on Teleflex in a research report on Friday, November 10th. They set an “overweight” rating and a $295.00 price objective on the stock. Finally, Morgan Stanley increased their price objective on Teleflex from $274.00 to $290.00 and gave the stock an “equal weight” rating in a research report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average target price of $277.78.

Teleflex (NYSE:TFX) traded up $9.38 during mid-day trading on Thursday, reaching $272.31. The company’s stock had a trading volume of 344,500 shares, compared to its average volume of 243,209. The company has a quick ratio of 3.70, a current ratio of 4.72 and a debt-to-equity ratio of 0.88. The company has a market cap of $12,270.00, a PE ratio of 49.15, a price-to-earnings-growth ratio of 1.94 and a beta of 1.09. Teleflex has a 1 year low of $162.79 and a 1 year high of $272.46.

In other news, CEO Benson Smith sold 2,000 shares of the stock in a transaction on Monday, December 4th. The stock was sold at an average price of $258.10, for a total transaction of $516,200.00. Following the sale, the chief executive officer now directly owns 76,634 shares of the company’s stock, valued at approximately $19,779,235.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director George Babich, Jr. sold 2,500 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $263.38, for a total value of $658,450.00. Following the sale, the director now directly owns 10,583 shares in the company, valued at $2,787,350.54. The disclosure for this sale can be found here. Over the last three months, insiders have sold 5,100 shares of company stock worth $1,324,942. 2.39% of the stock is currently owned by insiders.

A number of large investors have recently added to or reduced their stakes in TFX. Toronto Dominion Bank boosted its stake in Teleflex by 14.5% in the second quarter. Toronto Dominion Bank now owns 552 shares of the medical technology company’s stock valued at $115,000 after buying an additional 70 shares in the last quarter. Advisory Services Network LLC boosted its stake in Teleflex by 933.8% in the second quarter. Advisory Services Network LLC now owns 827 shares of the medical technology company’s stock valued at $172,000 after buying an additional 747 shares in the last quarter. Cornerstone Capital Management Holdings LLC. acquired a new stake in Teleflex in the second quarter valued at about $175,000. Archford Capital Strategies LLC boosted its stake in Teleflex by 29,025.0% in the second quarter. Archford Capital Strategies LLC now owns 1,165 shares of the medical technology company’s stock valued at $217,000 after buying an additional 1,161 shares in the last quarter. Finally, Coldstream Capital Management Inc. acquired a new stake in Teleflex in the third quarter valued at about $226,000. 89.29% of the stock is currently owned by institutional investors and hedge funds.

WARNING: “Brokerages Anticipate Teleflex Incorporated (TFX) Will Announce Quarterly Sales of $601.67 Million” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/brokerages-anticipate-teleflex-incorporated-tfx-will-announce-quarterly-sales-of-601-67-million/1812219.html.

Teleflex Company Profile

Teleflex Incorporated is a provider of medical technology products. The Company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company operates through six segments: Vascular North America; Anesthesia North America; Surgical North America; Europe, the Middle East and Africa (EMEA); Asia, and Original Equipment Manufacturer (OEM).

Get a free copy of the Zacks research report on Teleflex (TFX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teleflex (NYSE:TFX)

Receive News & Ratings for Teleflex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teleflex and related companies with Analyst Ratings Network's FREE daily email newsletter.